Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 965

1.

Newly approved and promising antidiabetic agents.

Combettes M, Kargar C.

Therapie. 2007 Jul-Aug;62(4):293-310. Epub 2007 Nov 6. Review.

PMID:
17983555
2.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
3.

Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.

Baggio LL, Drucker DJ.

Treat Endocrinol. 2002;1(2):117-25. Review.

PMID:
15765627
4.

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Abbatecola AM, Maggi S, Paolisso G.

Drugs Aging. 2008;25(11):913-25. doi: 10.2165/0002512-200825110-00002. Review.

PMID:
18947259
5.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
6.

Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes.

Sebokova E, Christ AD, Boehringer M, Mizrahi J.

Curr Top Med Chem. 2007;7(6):547-55. Review.

PMID:
17352676
7.

[The incretin effect: a new therapeutic target in type 2 diabetes].

Féry F.

Rev Med Brux. 2007 Sep;28(4):329-35. French.

PMID:
17958029
8.

Incretins and other peptides in the treatment of diabetes.

Todd JF, Bloom SR.

Diabet Med. 2007 Mar;24(3):223-32. Review.

PMID:
17263764
9.

Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

Gallwitz B.

Minerva Endocrinol. 2006 Jun;31(2):133-47. Review.

PMID:
16682937
10.

Enhancing incretin action for the treatment of type 2 diabetes.

Drucker DJ.

Diabetes Care. 2003 Oct;26(10):2929-40. Review.

PMID:
14514604
11.

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.

PMID:
19275672
12.
13.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
14.
15.

[Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].

Diamant M, Bunck MC, Heine RJ.

Ned Tijdschr Geneeskd. 2004 Sep 25;148(39):1912-7. Review. Dutch.

PMID:
15495988
16.

Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.

Gallwitz B.

Treat Endocrinol. 2005;4(6):361-70. Review.

PMID:
16318402
17.

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.

Triplitt C, Wright A, Chiquette E.

Pharmacotherapy. 2006 Mar;26(3):360-74. Review.

PMID:
16503716
18.

Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.

Mest HJ, Mentlein R.

Diabetologia. 2005 Apr;48(4):616-20. Epub 2005 Mar 16.

PMID:
15770466
19.

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.

Gallwitz B.

Handb Exp Pharmacol. 2011;(203):53-74. doi: 10.1007/978-3-642-17214-4_3. Review.

PMID:
21484567
20.

[Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].

Scheen AJ, Radermecker RP, Philips JC, Paquot N.

Rev Med Suisse. 2007 Aug 29;3(122):1884, 1886-8. Review. French.

PMID:
17896662
Items per page

Supplemental Content

Write to the Help Desk